INDEME: A targeted approach for vitiligo
Domain Health and wellbeing
Technology Metaomic
Applications
Therapy dedicated to depigmentation disorders such as VITILIGO
- Most common depigmenting disorder (0.5-1% of the world population)
- Stigma and major negative impact on patients’ quality of life
- No cure nor way of restricting the spread of the disease reported so far
Decription
Identification of a core molecule X1 involved in melanocytes loss
- Ex vivo analysis
- Higher X1 expression in vitiligo patients’ skin and sera compared to healthy subjects
- Vitiligo patients: Positive correlation between X1 level and the body surface area involved
- POC in vitro:
- Inhibitors targeting X1 prevent melanocyte loss in an in vitro model
Benefits
- Development of the first targeted therapy dedicated to vitiligo, an inflammatory skin disorder with high unmet medical needs
- Near-orphan status for drug development
Inventors
Katia BONIFACE
Julien SENESCHAL
Biotherapy of genetic diseases, inflammatory disorders and cancer (BMGIC, U 1035)
IP
This technology is protected by a patent application
Contact
Jean-Luc Chagnaud
%6a%6c%2e%63%68%61%67%6e%61%75%64%40%61%73%74%2d%69%6e%6e%6f%76%61%74%69%6f%6e%73%2e%63%6f%6d
